文献速递神经肌肉病

肌萎缩侧索硬化逆转表型的遗传关联研究

Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.
PubMed 文献 · Neurology · 2024-07-30

本研究对22例肌萎缩侧索硬化逆转表型患者进行全基因组测序,与103例典型进展型患者及140例独立验证队列比较,发现IGFBP7内含子单核苷酸变异rs4242007与逆转表型显著关联(OR=12.0,95%CI 4.1至34.6),该变异与额叶皮层IGFBP7表达降低相关。

要点

  • 逆转表型与IGFBP7非编码单核苷酸变异rs4242007显著关联,OR=12.0(95%CI 4.1至34.6)。
  • 3例逆转者纯合携带rs4242007,而243例典型进展者中无纯合携带者。
  • IGFBP7为IGF-1受体抑制剂,提示IGF-1通路可能为治疗机制。

核心结论

  • 逆转表型与IGFBP7非编码单核苷酸变异显著关联,该变异与IGFBP7表达降低相关,生物学上IGFBP7为IGF-1受体抑制剂,可能激活神经保护性IGF-1信号通路。

研究设计与样本

  • 全基因组关联研究,纳入22例有记录的ALS逆转表型患者,与CReATe联盟PGB研究中103例民族匹配的典型进展型ALS患者比较,并在Target ALS独立民族匹配全基因组测序数据集140例中验证。

主要发现

  • 两个遗传位点达到预设统计学显著性标准(双侧置换检验p≤0.01),精细定位后仍合理。
  • 第一位点领先单核苷酸变异为rs4242007(主要队列GWAS OR=12.0,95%CI 4.1至34.6),位于IGFBP7内含子,与IGFBP7启动子区单核苷酸变异近乎完全连锁不平衡。
  • 两个单核苷酸变异在eQTL数据集中均与额叶皮层IGFBP7表达降低相关。
  • 3例逆转者纯合携带rs4242007,而243例典型进展者中无纯合携带者。
  • 第二位点位于GRIP1附近,因缺乏对附近基因转录的关联效应,其重要性不确定。

关键数值与推荐

  • 预设统计学显著性标准为双侧置换检验p≤0.01。
  • 主要队列GWAS OR=12.0(95%CI 4.1至34.6),对应rs4242007。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 样本量小。
  • 第二位点位于GRIP1附近,因缺乏对附近基因转录的关联效应,其重要性不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The term "ALS Reversal" describes patients who initially meet diagnostic criteria for amyotrophic lateral sclerosis (ALS) or had clinical features most consistent with progressive muscular atrophy (PMA) but subsequently demonstrated substantial and sustained clinical improvement. The objective of this genome-wide association study (GWAS) was to identify correlates of this unusual clinical phenotype. METHODS: Participants were recruited from a previously created database of individuals with the ALS Reversal phenotype. Whole-genome sequencing (WGS) data were compared with ethnicity-matched patients with typically progressive ALS enrolled through the CReATe Consortium's Phenotype-Genotype-Biomarker (PGB) study. These results were replicated using an independent ethnically matched WGS data set from Target ALS. Significant results were further explored with available databases of genetic regulatory markers and expression quantitative trait loci (eQTL) analysis. RESULTS: WGS from 22 participants with documented ALS Reversals was compared with the PGB primary cohort (n = 103) and the Target ALS validation cohort (n = 140). Two genetic loci met predefined criteria for statistical significance (two-sided permutation p ≤ 0.01) and remained plausible after fine-mapping. The lead single nucleotide variant (SNV) from the first locus was rs4242007 (primary cohort GWAS OR = 12.0, 95% CI 4.1 to 34.6), which is in an IGFBP7 intron and is in near-perfect linkage disequilibrium with a SNV in the IGFBP7 promoter region. Both SNVs are associated with decreased frontal cortex IGFBP7 expression in eQTL data sets. Notably, 3 Reversals, but none of the typically progressive individuals (n = 243), were homozygous for rs4242007. The importance of the second locus, located near GRIP1, is uncertain given the absence of an associated effect on nearby gene transcription. DISCUSSION: We found a significant association between the Reversal phenotype and an IGFBP7 noncoding SNV that is associated with IGFBP7 expression. This is biologically relevant as IGFBP7 is a reported inhibitor of the insulin growth factor-1 (IGF-1) receptor that activates the possibly neuroprotective IGF-1 signaling pathway. This finding is limited by small sample size but suggests that there may be merit in further exploration of IGF-1 pathway signaling as a therapeutic mechanism for ALS. TRIAL REGISTRATION INFORMATION: This study was registered with ClinicalTrials.gov (NCT03464903) on March 14, 2018. The first participant was enrolled on June 22, 2018.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Crayle JI, Rampersaud E, Myers JR, et al. Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype. Neurology. 2024. PMID: 39079071. doi:10.1212/WNL.0000000000209696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。